{"id":1954,"date":"2019-11-29T07:58:29","date_gmt":"2019-11-29T06:58:29","guid":{"rendered":"https:\/\/www.ggkmedia.com\/?p=1954"},"modified":"2020-03-19T14:03:14","modified_gmt":"2020-03-19T13:03:14","slug":"double-bond-pharma-soker-patent-for-anvandning-av-jarnsuccinat","status":"publish","type":"post","link":"https:\/\/www.drugsson.com\/sv\/double-bond-pharma-soker-patent-for-anvandning-av-jarnsuccinat\/","title":{"rendered":"Double Bond Pharma s\u00f6ker patent f\u00f6r anv\u00e4ndning av j\u00e4rnsuccinat"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-background-repeat:repeat;--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:90px;--awb-padding-bottom:90px;--awb-background-color:#eaf7ff;--awb-border-sizes-top:0px;--awb-border-sizes-bottom:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:30px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-1\"><h3>Double Bond Pharma s\u00f6ker patent f\u00f6r anv\u00e4ndning av j\u00e4rnsuccinat<\/h3>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-bg-size:cover;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"--awb-padding-top:50px;--awb-padding-right:50px;--awb-padding-bottom:50px;--awb-padding-left:50px;--awb-bg-color:#ffffff;--awb-bg-color-hover:#ffffff;--awb-bg-size:cover;--awb-border-color:#25afb4;--awb-border-bottom:8px;--awb-border-style:solid;width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-text fusion-text-2\"><p>L\u00e4kemedelsbolaget Double Bond Pharma har l\u00e4mnat in en svensk patentans\u00f6kan f\u00f6r att skydda anv\u00e4ndning av j\u00e4rnsuccinat f\u00f6r vissa indikationer. Det framg\u00e5r av ett pressmeddelande.<\/p>\n<p>Bolaget rapporterade ig\u00e5r den 28 november om positiva resultat av en studie som utv\u00e4rderade Inofer, en medicinsk produkt mot j\u00e4rnbrist, hos patienter med hj\u00e4rtsvikt och j\u00e4rnbrist som inte har anemi.<\/p>\n<p>Double Bond Pharma har genom sitt dotterbolag Drugsson distributionsr\u00e4ttigheten f\u00f6r Inofer, j\u00e4rnsuccinat, i Sverige, Norge, Danmark och Finland.<\/p>\n<p><a href=\"https:\/\/www.spotlightstockmarket.com\/sv\/bolag\/irabout\/?companyid=1490\" target=\"_blank\" rel=\"noopener noreferrer\">L\u00e4s mer<\/a> om Double Bond Pharmaceutical International AB<\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-text fusion-text-3\"><h4>Nyhetsk\u00e4lla<\/h4>\n<\/div><div class=\"fusion-text fusion-text-4\"><p><a href=\"https:\/\/www.spotlightstockmarket.com\/sv\/market-overview\/nyheter\/nyhets-artikel\/?id=26352&amp;publisher=371\" target=\"_blank\" rel=\"noopener noreferrer\">Spotlight<\/a><\/p>\n<\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;margin-top:40px;width:100%;\"><\/div><div class=\"fusion-sep-clear\"><\/div><div class=\"fusion-sharing-box fusion-sharing-box-1 boxed-icons has-taglines layout-floated layout-medium-floated layout-small-floated\" style=\"background-color:#f6f6f6;--awb-layout:row;--awb-alignment-small:space-between;\" data-title=\"Double Bond Pharma s\u00f6ker patent f\u00f6r anv\u00e4ndning av j\u00e4rnsuccinat\" data-description=\"Double Bond Pharma s\u00f6ker patent f\u00f6r anv\u00e4ndning av j\u00e4rnsuccinat    L\u00e4kemedelsbolaget Double Bond Pharma har l\u00e4mnat in en svensk patentans\u00f6kan f\u00f6r att skydda anv\u00e4ndning av j\u00e4rnsuccinat f\u00f6r vissa indikationer. Det framg\u00e5r av ett pressmeddelande.Bolaget rapporterade ig\u00e5r den 28 november om positiva resultat av en studie som utv\u00e4rderade Inofer, en\" data-link=\"https:\/\/www.drugsson.com\/sv\/double-bond-pharma-soker-patent-for-anvandning-av-jarnsuccinat\/\"><h4 class=\"tagline\" style=\"color:#4c5166;\">Dela inl\u00e4gget<\/h4><div class=\"fusion-social-networks sharingbox-shortcode-icon-wrapper sharingbox-shortcode-icon-wrapper-1 boxed-icons\"><span><a href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharma-soker-patent-for-anvandning-av-jarnsuccinat%2F&amp;t=Double%20Bond%20Pharma%20s%C3%B6ker%20patent%20f%C3%B6r%20anv%C3%A4ndning%20av%20j%C3%A4rnsuccinat\" target=\"_blank\" rel=\"noreferrer\" title=\"Facebook\" aria-label=\"Facebook\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"Facebook\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-facebook awb-icon-facebook\" style=\"color:#ffffff;background-color:#3b5998;border-color:#3b5998;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/x.com\/intent\/post?text=Double%20Bond%20Pharma%20s%C3%B6ker%20patent%20f%C3%B6r%20anv%C3%A4ndning%20av%20j%C3%A4rnsuccinat&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharma-soker-patent-for-anvandning-av-jarnsuccinat%2F\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"X\" aria-label=\"X\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"X\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-twitter awb-icon-twitter\" style=\"color:#ffffff;background-color:#000000;border-color:#000000;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><span><a href=\"https:\/\/www.linkedin.com\/shareArticle?mini=true&amp;url=https%3A%2F%2Fwww.drugsson.com%2Fsv%2Fdouble-bond-pharma-soker-patent-for-anvandning-av-jarnsuccinat%2F&amp;title=Double%20Bond%20Pharma%20s%C3%B6ker%20patent%20f%C3%B6r%20anv%C3%A4ndning%20av%20j%C3%A4rnsuccinat&amp;summary=Double%20Bond%20Pharma%20s%C3%B6ker%20patent%20f%C3%B6r%20anv%C3%A4ndning%20av%20j%C3%A4rnsuccinat%20%20%20%20%20%20%20%0D%0A%0D%0AL%C3%A4kemedelsbolaget%20Double%20Bond%20Pharma%20har%20l%C3%A4mnat%20in%20en%20svensk%20patentans%C3%B6kan%20f%C3%B6r%20att%20skydda%20anv%C3%A4ndning%20av%20j%C3%A4rnsuccinat%20f%C3%B6r%20vissa%20indikationer.%20Det%20framg%C3%A5r%20av%20ett%20pressmeddelande.%0D%0A%0D%0ABolaget%20rapporterade%20ig%C3%A5r%20den%2028%20november%20om%20positiva%20resultat%20av%20en%20studie%20som%20utv%C3%A4rderade%20Inofer%2C%20en\" target=\"_blank\" rel=\"noopener noreferrer\" title=\"LinkedIn\" aria-label=\"LinkedIn\" data-placement=\"top\" data-toggle=\"tooltip\" data-title=\"LinkedIn\"><i class=\"fusion-social-network-icon fusion-tooltip fusion-linkedin awb-icon-linkedin\" style=\"color:#ffffff;background-color:#0077b5;border-color:#0077b5;border-radius:0px;\" aria-hidden=\"true\"><\/i><\/a><\/span><\/div><\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"--awb-bg-size:cover;width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1954"}],"collection":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/comments?post=1954"}],"version-history":[{"count":1,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1954\/revisions"}],"predecessor-version":[{"id":1955,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/posts\/1954\/revisions\/1955"}],"wp:attachment":[{"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/media?parent=1954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/categories?post=1954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugsson.com\/sv\/wp-json\/wp\/v2\/tags?post=1954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}